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Metabolism alterations are associated with the loss of mitochondrial 
function in tumor cells. Current research discuss whether such loss is 
evident in function itself, or if cells can provide maximum stability to 
its functions. More studies are needed to determine the behavior of 
cancer in mitochondria. Tumor cells experience a limitation of oxygen 
and mutations in oncogenes, tumor suppressor genes and enzymes of 
the glycolytic pathway and/or mitochondrial oxidative metabolism, 
thus allowing the formation of aggressive cancer. This article is the 
result of a literature review of the scientific evidence that has been 
presented in the latest research on cancer and mitochondrial function.
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| Resumen |
Se ha descrito que algunas alteraciones del metabolismo están 
asociadas con la pérdida de función mitocondrial en células tumorales. 
Aún se discute si tal pérdida se evidencia en la función o si la célula 
brinda máxima estabilidad a sus funciones, se requieren más estudios 
para conocer el comportamiento del cáncer en la mitocondria. Cuando 
tiene limitación de oxígeno y mutaciones en oncogenes, genes 
supresores de tumor y enzimas de la vía glucolítica o del metabolismo 
oxidativo mitocondrial, la célula tumoral permite la formación de un 
cáncer agresivo. Este artículo es producto de la revisión bibliográfica 
de la evidencia científica que se ha presentado en las últimas 
investigaciones respecto al cáncer y la función mitocondrial.
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Introduction
The genes which encode the machinery that generates energy in 
the mitochondria are tumor suppressors; when they do not function 
properly, some processes and pathways that lead to cancer may 
be triggered. Mitochondria are organelles that have mitochondrial 
DNA (mtDNA), which is inherited only from the mother during the 
fertilization process. These organelles are the “energetic generators” 
of healthy cells, such as those that have their metabolisms encoded 
to be apoptosis inhibitors. (1,2) 
Mitochondria regulate and coordinate apoptosis activation, 
hence their importance for the study and research on therapies 
against cancer. When mitochondria deregulate, the onset of 
diseases such as cancer is stimulated due to an increased catabolic 
process, not to mention their role in neurodegenerative diseases, 
which are associated with abnormal mitochondrial function and 
apoptosis. (1,2) 
Mitochondria and cancer
mtDNA mutagenesis is involved in a wide arrange of tumor processes, 
including renal adenocarcinoma, colon cancer, head and neck tumors, 
astrocytic tumors, thyroid tumors, breast tumors, ovarian, prostate and 
bladder cancer tumors, neuroblastomas, and oncocytomas. Many mtDNA 
mutations in cancer cells clearly inhibit oxidative phosphorylation. 
Although some of these cancers have ancestral polymorphisms 
associations, others may be cancer cell mutations. (3-6) (table 1).
Cancer cells acquire enough ATP to support proliferation and 
to function endlessly, which has captivated scientists for nearly a 
century. Otto Warburg et al. conducted the first quantitative study 
on cancer cell metabolism in the 1920s. (7,8)
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Table 1. Generalities of the role of cancer in mitochondrial function.
1
In cancer, the metabolism of mitochondria reinforces antioxidant defenses, in order 
to compensate for the activation of the anaerobic pathway and not to induce cells 
to apoptosis by damaging free radicals.
2
Mitochondrial DNA encodes genes that may contribute to the development of 
cancer; such mutations provide metabolic adaptability to the cancer cell. 
3
Myc oncogene activation, tumor suppressor genes inactivation —such as p53—, 
and adaptation to hypoxia via the HIF-1 pathway are mechanisms involved in 
the Warburg effect.
4
Myc activation allows mitochondria to have little depletion of the enzymes that 
metabolize to create energy from lipids and fatty acids. 
5
In cancer, the pyruvate dehydrogenase complex is regulated to adjust the flow 
of acetyl-CoA and the reduction equivalents in the mitochondria, and to sustain 
the aerobic glycolysis pathway as anaerobic without inducing apoptosis genes 
and processes.
6
Mitochondria regulate genes and proteins through their endoplasmic reticulum 
to reduce the absorption of mitochondrial Ca+2, aiming to stabilize the transition 
pore of mitochondrial permeability, to not induce the pathways of apoptosis, and 
to increase cytosolic Ca+2. 
7
Mitochondrial DNA reduction is a cellular process of cancer that increases cytosolic 
Ca+2, which does not occur at mitochondrial level, in order to activate the 
signaling pathways that stimulate nuclear proteins and the membrane potential of 
the mitochondria. This allows invasive and tumor growth of the cell by synthesizing 
ATP at its maximum cellular function to create specific proteins and activate 
signaling pathways that allow metastasis. 
8
The energy metabolism of any proliferative cell, whether carcinogenic or not, must 
be based on active glycolysis. Stating that tumor cells consume more glucose than 
non-tumor cells is not recent. Tumor cells use and form embryonic iso-zygotes to 
have a very active metabolic pathway. 
9
There are several forms of regulatory glycolytic enzymes. The most predominant in 
the embryonic tissue are replaced by the "normal" versions at birth. It has been 
observed that, in cancer, the embryonic forms of hexokinase, phosphofructokinase, 
the N2 form of pyruvate kinase and the anaerobic (A) variety of LDH are 
predominant.
Source: Own elaboration based on the data obtained in the study.
Cells can obtain energy through a process called glycolysis that 
consists of anaerobic fermentation, in which the waste products of 
that fermentative process are pyruvate and lactic acid. (9,10) Tumor 
tissues metabolize approximately ten times more glucose into lactate 
at a given time than normal tissues. (6,8) Warburg hypothesized that 
effective cellular respiration caused by mitochondrial damage leads 
to carcinogenesis. (9,10) 
Warburg’s effect describes that cancer cells use glycolysis 
followed by lactic fermentation as an energy source, even if there 
is an appropriate amount of oxygen for respiration. (1,11) In other 
words, instead of developing a complete respiration process in the 
presence of adequate amounts of oxygen, cancer cells ferment and 
continue to mutate to preserve their tumoral domain. (12)
At the cellular level, tumors have survival advantages due to lactate 
secretion. (4,13,14) Lactic acid confers invasive properties to tumor 
cells, affecting the normal structure of tissues. (15) Additionally, 
the expression of vascular endothelial growth factor and its receptor 
(VEGF and VEGFR, respectively) responds to different stimuli 
to generate new blood vessels from preexisting ones. (1,16-18) 
VEGFα stimulates vascular endothelial cell growth, cell survival 
and proliferation regulated by the nuclear and mitochondrial action of 
the cell. Furthermore, VEGF and gene mutations leading to activate 
metalloproteinases to degrade the extracellular matrix allow greater 
metastatic action. (19) Recent studies suggest that VEGF can protect 
cells from apoptosis and increase their resistance to conventional 
chemotherapy and radiotherapy. (20,21) 
Similarly, metastasis is of great importance since most of cancer 
deaths occur because primary cancer spreads to distant sites. In most 
cases, cancer patients with localized tumors have a better survival 
rate than patients with cancer and metastatic tumors. (22-25) It is also 
suggested that the increase of oncogene mutations, tumor suppressor 
genes and enzymes of the glycolytic pathway and/or mitochondrial 
oxidative metabolism (Myc, Akt, p53, HIF1-α) allow to turn cancer 
cells into efficient metastatic cells. (3)
The hypoxia-inducible factor (HIF-1) protein is normally activated 
in response to certain cellular crises, such as lack of oxygen. However, 
in the case of mitochondria with abnormal and tumor mechanisms, 
the expression of HIF-1 that is perpetuated in the presence of 
damage signs in the SDH gene is stimulated. This is caused by the 
cell following already established oncogenes guidelines to carry out 
a unique type of homeostasis for cancer and to supply high levels 
of glucose and oxygen to replicate itself without control. (1,26,27) 
Variety of metabolic fuels for tumor cells 
A wide variety of metabolic fuels can be observed in tumor pathways, 
in which tumor cells are able to utilize different bioenergetic 
substrates, including glutamine, glucose, fatty acids, ketone bodies, 
and acetate. These substrates can be provided by the stromal cells in 
the microenvironment. (28) Particularly, glutamine and glucose can 
provide building blocks for the synthesis of many biomolecules that 
allow the regulation of oncogenesis processes. It is worth mentioning 
that metabolic enzymes with mutations are found in several tumors and 
in the oncometabolites accumulated in different types of tumors. (28,29)
Cancer cells also show increased demand for fatty acids other than 
glutamine. (6,30) Fatty acids can be synthesized endogenously or 
taken from exogenous sources. For example, prostate tumors import 
less glucose than other tumors, (31) therefore, β-oxidation of fatty 
acids is an important source of energy. (32,33) 
Moreover, two recent studies showed that acetate is a bioenergetic 
substrate for glioblastoma and brain metastases. (34) Catabolism in 
stromal and adipocyte cells provides fuel and building blocks for 
the anabolic growth of cancer cells through metabolic coupling. (35) 
Cancer cells and independence
In 2000 and 2011, Hanahan and Weinberg summarized an extensive 
research on cancer and the top 10 characteristics of cancer and 
its correlation with mitochondria (table 2). (36-39) These authors 
describe how cancer cells can be stimulated by infectious phenomena, 
inflammation, viruses, toxic substances and other actions that allow 
the proliferation of anomalous cells. 
In these works, they emphasize that the centralist vision of cancer 
has transcended the anomalous production of cellular mutations, and 
also consider that tumor evolution is based on the appearance of changes 
and the stress in the cellular ecosystem that induces the genome to 
instability and produces mutations, signal activations with erroneous 
sequences and mechanisms of evasion in the immune system. (23,40)
With this in mind, tumors develop when normal cells undergo genetic 
alterations that affect growth points. This results in a disproportionate 
growth that eventually leads to the onset of the disease. As pre-
malignant cells evolve to cancer cells, the environment surrounding 
the tumor coevolves as well, creating a dynamic circuit of tumor-
microenvironment interaction. (23,40)
Approximately 80% of cancers are carcinomas, that is, cancers that 
originate in the epithelial tissue, and their main support is the stroma, 
which nourishes, protects and supports the epithelial tissue. It could 
be said that stroma is the connective tissue that forms the framework 
of an organ, and includes the extracellular matrix and the cells that 
synthesize it (fibroblasts, endothelial cells, etc.). (23)
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Table 2. Top 10 characteristics of cancer and their correlation to mitochondria.
Cancer characteristics
Self-sufficiency of growth 
signals






Metastasis of other tissues
Fostering inflammation
Genomic and mutational 
instability
Energy deregulation
Evasion of the immune system
Source: Own elaboration based on (23).
Cancer cells communicate with their environment while 
exchanging soluble molecules with the paracrine stroma, which 
turns stroma into the support of the tumor and, therefore, facilitates 
its progression. It is worth mentioning that the success of the tumor 
depends on its ability to survive in an inhospitable microenvironment. 
Besides stromal cells, inflammatory cells may also be found in this 
microenvironment. (39,40)
Why to continue research on mitochondria?
Currently, cancer studies focus their efforts on finding a molecular 
mechanism that links mitochondrial mutations to tumor formation. 
Research seeks to increase the understanding of the molecular basis 
of cancer, with the purpose of finding new prevention, diagnosis and 
treatment methods for the disease. 
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